Published • loading... • Updated
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
The acquisition adds navtemadlin, a Phase III add-on therapy that Ipsen says could improve outcomes for myelofibrosis patients with poor ruxolitinib response.
Summary by WBOC 16
6 Articles
6 Articles
The Toronto Star+4 Reposted by 4 other sources
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis.
·Toronto, Canada
Read Full Article
The laboratory pays 385 million euros for this specialist in hemato-oncology, but the shareholders of biotech could receive up to 1.3 billion additional dollars.
Coverage Details
Total News Sources6
Leaning Left2Leaning Right2Center1Last UpdatedBias Distribution40% Left, 40% Right
Bias Distribution
- 40% of the sources lean Left, 40% of the sources lean Right
40% Right
L 40%
C 20%
R 40%
Factuality
To view factuality data please Upgrade to Premium
